Abdominal ObesityNCT07125716
Suture Length Effects in Acupoint Implantation for Abdominal Obesity
A study testing 1 inch and 0.5 inch in people with Abdominal Obesity and Obesity, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
Trial summary
Obesity is a metabolic disorder and has become a global health issue with a steadily increasing prevalence. According to the Health Promotion Administration's statistical report, the overweight and obesity rate among adults in Taiwan was 50.3% between 2017 and 2020. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Abdominal Obesity, Obesity
- What is being tested?
- 1 inch and 0.5 inch
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 78 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Aug 2025to 31 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Willing to sign a written informed consent form
- BMI ≥27 kg/m² (Ministry of Health and Welfare standard)
- Waist circumference ≥90 cm for men
- Waist circumference ≥80 cm for women
- Age between 18 and 65 years
Who cannot join
- Endocrine disorders (thyroid disease, pituitary disorders, and diabetes)
- Autoimmune diseases (systemic lupus erythematosus, Sjögren's syndrome, and rheumatoid arthritis)
- Heart diseases (heart failure, arrhythmia, etc.)
- Abnormal liver function
- Abnormal kidney function
- Stroke within the past year
Show all 11Show fewer
- Pregnant or breastfeeding women
- Coagulation disorders
- Tumors
- Participation in weight loss treatment within the past 6 months
- Any other condition deemed unsuitable for the trial by the physician
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
Chang-Geng Medical Foundation Keelung Chang-Geng Memorial Hospital
Keelung
About this study
Official title: Effects of Different Lengths of Surgical Sutures in Acupoint Catgut Implantation on Simple Abdominal Obesity in Adults
Obesity is a metabolic disorder and has become a global health issue with a steadily increasing prevalence. According to the Health Promotion Administration's statistical report, the overweight and obesity rate among adults in Taiwan was 50.3% between 2017 and 2020. Based on the Ministry of Health and Welfare's criteria, a BMI ≥27 kg/m² is classified as obese.
Studies have shown that acupuncture can effectively reduce body weight with low cost and minimal side effects. Acupoint catgut embedding is a treatment method that combines traditional meridian acupuncture with modern medical materials by implanting surgical sutures into acupoints to provide continuous stimulation.
Read more
A 2022 systematic review found that catgut embedding is more effective than traditional acupuncture, requires fewer treatment sessions, and has a high safety profile. However, no studies have yet investigated whether different lengths of implanted surgical sutures affect treatment outcomes.
This study is a single-center, double-blind, randomized controlled trial aimed at identifying the optimal suture length for acupoint catgut embedding, in order to enhance its efficiency and therapeutic effect.
- Conditions
- Abdominal Obesity, Obesity
- Being tested
- 1 inch, 0.5 inch
- Medical subject headings
- Obesity, Abdominal, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
1 inchDevice
1 inch suture length
0.5 inchDevice
0.5 inch suture length
| Study group | Role | What they receive |
|---|---|---|
| 1 inch suture length | Experimental | Not described Receives: Device: 1 inch |
| 0.5 inch suture length | Active comparator | Not described Receives: Device: 0.5 inch |
What is being measured
The primary outcome is the main question the study is designed to answer.
Waist circumference
Measured: 1 week,4 week,8 week
Secondary outcomes (5)
hip circumference
Measured: 1 week,4 week,8 week
weight
Measured: 1 week,4 week,8 week
BMI
Measured: 1 week,4 week,8 week
VAS
Measured: 1 week,4 week,8 week
Ultrasound Fat Thickness
Measured: 1 week,4 week,8 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Aug 2025
- Study start1 Aug 2025
- Primary completion30 Jun 2026 (estimated)
- Study completion31 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Abdominal ObesityStudies of the same condition, open and under way.
- More trials run by Chang Gung Memorial HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 78 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chang Gung Memorial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07125716
- Sponsor's protocol ID
- 202500161A3
- Status last verified
- Apr 2025
- First submitted
- 10 Aug 2025
- Last updated
- 15 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Different Lengths of Surgical Sutures in Acupoint Catgut Implantation on Simple Abdominal Obesity in Adults
- ClinicalTrials.gov ID
- NCT07125716
- Acronym / sponsor ID
- 202500161A3
- Conditions
- Abdominal Obesity, Obesity
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 78 participants (estimated)
- Lead sponsor
- Chang Gung Memorial HospitalUniversity, hospital or other
- Study start
- 1 Aug 2025 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 31 Jul 2026 (estimated)
- First posted
- 15 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obesity is a metabolic disorder and has become a global health issue with a steadily increasing prevalence. According to the Health Promotion Administration's statistical report, the overweight and obesity rate among adults in Taiwan was 50.3% between 2017 and 2020. Based on the Ministry of Health and Welfare's criteria, a BMI ≥27 kg/m² is classified as obese.
Studies have shown that acupuncture can effectively reduce body weight with low cost and minimal side effects. Acupoint catgut embedding is a treatment method that combines traditional meridian acupuncture with modern medical materials by implanting surgical sutures into acupoints to provide continuous stimulation.
A 2022 systematic review found that catgut embedding is more effective than traditional acupuncture, requires fewer treatment sessions, and has a high safety profile. However, no studies have yet investigated whether different lengths of implanted surgical sutures affect treatment outcomes.
This study is a single-center, double-blind, randomized controlled trial aimed at identifying the optimal suture length for acupoint catgut embedding, in order to enhance its efficiency and therapeutic effect.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 inch suture length | Experimental | Device: 1 inch |
| 0.5 inch suture length | Active comparator | Device: 0.5 inch |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Willing to sign a written informed consent form
- BMI ≥27 kg/m² (Ministry of Health and Welfare standard)
- Waist circumference ≥90 cm for men
- Waist circumference ≥80 cm for women
- Age between 18 and 65 years
Key exclusion criteria (11 listed)
- Endocrine disorders (thyroid disease, pituitary disorders, and diabetes)
- Autoimmune diseases (systemic lupus erythematosus, Sjögren's syndrome, and rheumatoid arthritis)
- Heart diseases (heart failure, arrhythmia, etc.)
- Abnormal liver function
- Abnormal kidney function
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 1 inch1 inch suture length | Device | 1 inch suture length |
| 0.5 inch0.5 inch suture length | Device | 0.5 inch suture length |
Primary outcome
Waist circumference
Time frame: 1 week,4 week,8 week
5 secondary outcomes
hip circumference
Time frame: 1 week,4 week,8 week
weight
Time frame: 1 week,4 week,8 week
BMI
Time frame: 1 week,4 week,8 week
VAS
Time frame: 1 week,4 week,8 week
Ultrasound Fat Thickness
Time frame: 1 week,4 week,8 week
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2025.
Related trials for Abdominal Obesity
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Overweight, Prediabetic State
Active, not recruiting
Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery
COPD Exacerbation, Oxygen Toxicity
RecruitingObservational study
Asprosin and miRNA Expression in Young Women With Metabolic Syndrome
Metabolic Syndrome, Insulin Resistance
Not yet recruiting
Study on the Mechanism of Central Obesity Induced by Sleep Restriction and the Therapeutic Effect of n-3 Polyunsaturated Fatty Acid: a Randomized, Double-blind, Placebo-controlled Trial (COSPA Study)
Sleep Deprivation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 1 inch and 0.5 inch in people with Abdominal Obesity and Obesity, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 15 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Waist circumference (time frame: 1 week,4 week,8 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2025.